FindTrial
Sign In

Clinical role of PPAR gamma activator (pioglitazone) in reducing the gastric phlogosis in patiens with istological gastritis.

Clinical role of PPAR gamma activator (pioglitazone) in reducing the gastric phlogosis in patiens with istological gastritis.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001218-42-IT
Enrollment
Unknown
Registered
2005-11-08
Start date
2005-01-17
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of patients with gastric phlogosis (infected by Helicobacter pylori) MedDRA version: 9.1 Level: LLT Classification code 10017904 Term: Gastroenteritis helicobacter

Interventions

Trade Name: ACTOS*28CPR 15MG Pharmaceutical Form: Tablet INN or Proposed INN: Pioglitazone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15-

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026